Patents Assigned to Vet Therapeutics, Inc.
  • Patent number: 9616120
    Abstract: The invention provides antibody to canine or feline or equine antigens. Specifically, antibodies directed to canine CD20 which have been caninized or felinized are provided. Also provided are methods for preparing high affinity antibodies to canine and feline CD20 as well as methods for treating B cell disorders in companion animals.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: April 11, 2017
    Assignee: VET THERAPEUTICS, INC.
    Inventor: Genevieve Hansen
  • Patent number: 8652470
    Abstract: The invention provides antibody to canine or feline or equine antigens, e.g., canine CDS2, and methods of making and using antibodies as described.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: February 18, 2014
    Assignee: Vet Therapeutics, Inc.
    Inventor: Genevieve Hansen
  • Patent number: 8569460
    Abstract: The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more FcRs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: October 29, 2013
    Assignee: Vet Therapeutics, Inc.
    Inventor: Geneviève Hansen
  • Patent number: 8337842
    Abstract: The invention provides heterochimeric antibodies and/or fragments thereof comprising (i) hypervariable region sequences wholly or substantially corresponding to sequences found in antibodies from a donor species; (ii) constant region sequences wholly or substantially corresponding to sequences found in antibodies from a target species which is different from the donor species; and (iii) heavy and/or light chain variable framework sequences which contain at least three non-CDR residues corresponding to sequences found in antibodies from a target species and at least three contiguous non-CDR residues corresponding to sequences found in antibodies from a donor species. The invention further provides antibody to canine or feline or equine antigens, e.g., CD20 or CD52, and methods of making and using antibodies as described.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: December 25, 2012
    Assignee: Vet Therapeutics, Inc.
    Inventor: Geneviève Hansen